Darunavir Ethanolate
Recommended · restricted Infectious diseaseAuthority RequiredLater-line line
Treatment of HIV-1 infection in antiretroviral treatment-experienced patients with evidence of viral replication and/or CD4 cell counts <500 cells/mm³, who have failed previous treatment with or have resistance to at least 3 different antiretroviral regimens.
1
Submissions
2007–07
On the record
$15k–45k
ICER range
1 sourced ICER · 2007
ICER stated
Cost basis
Access path
- Jul 2007Recommended · restricted
vs tipranavir/ritonavir (primary); standard care protease…
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
The PBAC noted that the submission calculated the base case modelled incremental discounted cost/extra discounted QALY for darunavir versus tipranavir to be between $15,000 - $45,000 per/QALY, which was considered acceptable by the PBAC. PBAC · 2007
Decision context
PopulationAntiretroviral treatment-experienced patients with HIV-1 infection, evidence of viral replication (viral load >10,000 copies/mL) and/or CD4 <500 cells/mm³, who have failed or are resistant to at least 3 different antiretroviral regimens including at least 2 protease inhibitors.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2007 | Recommended · restricted | tipranavir/ritonavir (primary); standard care protease inhibitors (secondary) | $15k–45k | RCT · Virological_response |